Immune Checkpoint Inhibitors Market Size, Demand, Forecast To 2033

(MENAFN- Straits Research) Introduction

Immune checkpoint inhibitors (ICIs) are a class of drugs that enhance the immune system's ability to recognize and attack cancer cells. These inhibitors work by blocking specific proteins-such as PD-1, PD-L1, and CTLA-4, that act as checkpoints and prevent immune cells from effectively targeting tumors. By inhibiting these checkpoints, ICIs enable the immune system to mount a stronger and more sustained response against cancer, providing a promising therapeutic option for several types of cancer, including melanoma, lung, and kidney cancers.

Market DynamicsGrowing adoption of combinational therapies drives the global market

Increasing combination therapies with ICIs are driving the market as combining ICIs with other treatments, like chemotherapy or targeted therapies, has shown improved efficacy for various cancers. This approach addresses resistance issues associated with monotherapy ICIs, expanding their applicability across different cancer types.

• For example, Merck's Keytruda (pembrolizumab) combined with chemotherapy is now a standard treatment for advanced non-small cell lung cancer (NSCLC), significantly improving survival rates compared to chemotherapy alone.

Expanding ICI applications in rare and hard-to-treat cancers creates tremendous opportunities

The expanding use of ICIs in rare and hard-to-treat cancers represents a promising growth avenue. Clinical trials are currently targeting cancers with limited treatment options, such as gastric and head-and-neck cancers. Positive outcomes from these trials could lead to new approvals, broadening the scope of ICI therapies globally.

• For instance, the FDA recently approved Keytruda for certain patients with head-and-neck squamous cell carcinoma, demonstrating the potential for ICIs in new indications and underscoring their role in advancing cancer treatment options.

Regional Analysis

North America leads the immune checkpoint inhibitors (ICI) market, commanding the largest revenue share due to a combination of advanced healthcare infrastructure, substantial research and development investments, and significant adoption of cutting-edge oncology treatments. Strong support from regulatory bodies, such as the FDA, for expedited drug approvals plays a crucial role in accelerating the availability of new therapies. The high prevalence of cancer in the region further drives demand for effective treatment options.

Moreover, North America's emphasis on personalized medicine, along with the presence of key industry players, facilitates the rapid integration of innovative therapies into clinical practice. This strategic focus on tailored treatment approaches not only enhances patient outcomes but also solidifies North America's dominance in the ICI market. The collaboration between academia, industry, and healthcare providers in this region continues to foster advancements in cancer therapies, positioning it as a leader in the global landscape of immune checkpoint inhibitors.

Key Highlights

• The global immune checkpoint inhibitors market size was valued at USD 62.51 billion in 2024 and is projected to reach an estimated value of USD 189.40 billion by 2033, exhibiting a CAGR of 11.98% during the forecast period (2025-2033).
• By product type, the global immune checkpoint inhibitors market is segmented into PD-1 inhibitors, PD-L1 inhibitors, CTLA-4 inhibitors, and others. The PD-1 inhibitor segment leads the global market.
• By application, the global market is segmented into lung cancer, breast cancer, bladder cancer, melanoma, cervical cancer, colorectal cancer, Hodgkin lymphoma, and others. The lung cancer segment dominates the global immune checkpoint inhibitors industry.
• By distribution channel, the global market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment dominates the market.
• North America is the most significant global market shareholder.

Competitive Players

Merck & Co. Inc.

BeiGene Ltd.

F. Hoffmann-La Roche Ltd.

Regeneron Pharmaceuticals Inc.

GlaxoSmithKline plc

Bristol-Myers Squibb Company

Merck KGaA

Innovent Biologics Inc.

AstraZeneca plc

Shanghai Junshi Biosciences Co. Ltd.

Incyte Corporation

Immutep Ltd

Eli Lilly and Company

Sanofi

Pfizer Inc Recent Developments

• In September 2024, Merck announced that the U.S. FDA approved KEYTRUDA, its anti-PD-1 therapy, in combination with pemetrexed and platinum chemotherapy, for first-line treatment of adult patients with unresectable advanced or metastatic malignant pleural mesothelioma (MPM).

Segmentation

By Type

PD-1 Inhibitor

PD-L1 Inhibitor

CTLA-4 Inhibitor

Others

By Applications

Lung Cancer

Breast Cancer

Bladder Cancer

Melanoma

Colorectal Cancer

Hodgkin Lymphoma

Cervical Cancer

Others

By Distribution Channel

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

By Region

North America

Europe

Asia-Pacific

Latin America

The Middle East and Africa

MENAFN04112024004597010339ID1108848553